To our knowledge, PYR and AQ have yet to be specifically assessed in endothelium, as prior studies have primarily evaluated their STAT3 inhibitory effects on tumor cells of epithelial origin (Cheng et al., 2020; Coates et al., 2020; Khan et al., 2018; Lin et al., 2018; Liu et al., 2019a,b; Wu et al., 2020; Xiang et al., 2016; Zhou et al., 2020). Here, STAT3 is linked to neoplasm.